Viropharma Incorporated
EXTON, Pennsylvania, December 12, 2011 -
Clinicians and carers of children and adolescents suffering from prolonged, acute, convulsive seizures now have access to Buccolam (midazolam oromucosal solution), a newly approved rescue medication to treat prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age.[1] For infants between three to six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.
EXTON, Pennsylvania, November 15, 2011 -
- Completion Follows European Marketing Authorization and Confirmation of Orphan Drug Designation for Plenadren (Hydrocortisone, Modified Release Tablet) -
ViroPharma Incorporated (NASDAQ: VPHM) today announced that it completed its acquisition of DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy.
EXTON, Pennsylvania, October 27, 2011 -
- Positive CHMP Opinion Adopted for Product to Treat Adrenal Insufficiency, an Orphan Disease with Limited Treatment Options -
ViroPharma Incorporated (NASDAQ: VPHM) today announced that it has signed a definitive agreement to acquire DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy.
EXTON, Pennsylvania, September 6, 2011 -
- Approval Offers Convenient Alternative to Treat Seizures in Children and Adolescents -
- First Ever Product Approved through European Commission's Centralized Pediatric Use Marketing Authorization (PUMA) -
ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted a Centralized Pediatric Use Marketing Authorization (PUMA) for Buccolam (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age.
EXTON, Pennsylvania, June 24, 2011 -
ViroPharma Incorporated (Nasdaq: VPHM) today announced that the
Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) has adopted a positive opinion
recommending approval of a Pediatric Use Marketing Authorization
(PUMA) for Buccolam (midazolam, oromucosal solution), for
treatment of prolonged, acute, convulsive seizures in infants,
toddlers, children and adolescents, from 3 months to less than 18
years.
More News
- ViroPharma’s Cinryze (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
- Nine Abstracts Relating to Cinryze(R) (C1 Esterase Inhibitor [human]) Data Presented at 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI)
- Approval Recommended for Three Indications: Routine Prevention, Pre- Procedure Prevention, and Treatment in Patients with Hereditary Angioedema (HAE) -
- Cinryze(R) (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
- ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
- ViroPharma Announces Acceptance of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Marketing Authorization Application (MAA) by European Medicines Agency (EMA)